Literature DB >> 18311759

The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology.

M S Krathen1, J Dunham, E Gaines, J Junkins-Hopkins, E Kim, S L Kolasinski, C Kovarik, J Kwan-Morley, J Okawa, K Propert, N Rogers, M Rose, P Thomas, A B Troxel, A Van Voorhees, J Von Feldt, A L Weber, V P Werth.   

Abstract

OBJECTIVE: To evaluate the validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) for use by rheumatologists via reliability testing, and to extend the validation for dermatologists.
METHODS: Fourteen subjects with cutaneous lupus erythematosus (CLE; n = 10), a mimicker skin disease only (a cutaneous lesion that may appear clinically similar to CLE; n = 1), or both (n = 3) were rated with the CLASI by academic-based dermatologists (n = 5) and rheumatologists (n = 5).
RESULTS: The dermatology intraclass correlation coefficient (ICC) was 0.92 for activity and 0.82 for damage; for rheumatology the ICC was 0.83 for activity and 0.86 for damage. For intrarater reliability, the dermatology Spearman's rho was 0.94 for activity and 0.97 for damage; for rheumatology the Spearman's rho was 0.91 for activity and 0.99 for damage.
CONCLUSION: Our data confirm the reliability of the CLASI when used by dermatologists and support the CLASI as a reliable instrument for use by rheumatologists.

Entities:  

Mesh:

Year:  2008        PMID: 18311759      PMCID: PMC9078899          DOI: 10.1002/art.23319

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Measuring the activity of the disease in patients with cutaneous lupus erythematosus.

Authors:  A Parodi; C Massone; M Cacciapuoti; M G Aragone; P Bondavalli; G Cattarini; A Rebora
Journal:  Br J Dermatol       Date:  2000-03       Impact factor: 9.302

2.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors:  Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

Review 3.  The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus.

Authors:  R D Sontheimer
Journal:  Lupus       Date:  1997       Impact factor: 2.911

Review 4.  Measurement of systemic lupus erythematosus activity in clinical research.

Authors:  M H Liang; S A Socher; W N Roberts; J M Esdaile
Journal:  Arthritis Rheum       Date:  1988-07

Review 5.  Lupus erythematosus: systemic and cutaneous manifestations.

Authors:  Naomi Rothfield; Richard D Sontheimer; Megan Bernstein
Journal:  Clin Dermatol       Date:  2006 Sep-Oct       Impact factor: 3.541

6.  A retrospective biopsy study of the clinical diagnostic accuracy of common skin diseases by different specialties compared with dermatology.

Authors:  Klaus Sellheyer; Wilma F Bergfeld
Journal:  J Am Acad Dermatol       Date:  2005-05       Impact factor: 11.527

7.  Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child.

Authors:  A P Oranje; J F Stalder; A Taïeb; C Tasset; M de Longueville
Journal:  Pediatr Allergy Immunol       Date:  1997-02       Impact factor: 6.377

Review 8.  Clinical course and prognosis of cutaneous lupus erythematosus.

Authors:  Beate Tebbe
Journal:  Clin Dermatol       Date:  2004 Mar-Apr       Impact factor: 3.541

Review 9.  Current concepts in validity and reliability for psychometric instruments: theory and application.

Authors:  David A Cook; Thomas J Beckman
Journal:  Am J Med       Date:  2006-02       Impact factor: 4.965

  9 in total
  26 in total

Review 1.  B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Authors:  R John Looney
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

2.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

3.  The impact of skin damage due to cutaneous lupus on quality of life.

Authors:  S M Verma; J Okawa; K J Propert; V P Werth
Journal:  Br J Dermatol       Date:  2014-02       Impact factor: 9.302

4.  Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

Authors:  Aileen Y Chang; Evan W Piette; Kristen P Foering; Thomas R Tenhave; Joyce Okawa; Victoria P Werth
Journal:  Arch Dermatol       Date:  2011-07-18

5.  Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Renato Goreshi; Rachel Klein; Joyce Okawa; Mathew Rose; Andrew Cucchiara; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

Review 6.  Pitfalls and opportunities in measuring patient outcomes in lupus.

Authors:  Meenakshi Jolly
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 7.  [Systemic lupus erythematosus. Target criteria for treatment].

Authors:  T Alexander; R Biesen; A Jacobi; B Hoyer; A Bruns; F Hiepe
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

8.  The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al.

Authors:  Michael Krathen; Joerg Albrecht; Victoria P Werth
Journal:  Arthritis Rheum       Date:  2008-04-15

Review 9.  Cutaneous lupus erythematosus: diagnosis and treatment.

Authors:  L G Okon; V P Werth
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

10.  Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.

Authors:  M Yassaee; D Fiorentino; J Okawa; L Taylor; C Coley; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2009-10-26       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.